Program
Immunoglobulins
Also written as “IgPro10”, “TAK-771” and “Immunoglobulins Intravenous (Human)”.
Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Agammaglobulinemia · Scleroderma, Diffuse · Purpura, Thrombocytopenic, Idiopathic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 111 open or running | phase 4since Jul 7, 2011 | Sep 12, 2005 | Dec 20, 2029phase 4 · NCT03684018 |
| Takeda | 60 open or running | phase 3since Sep 11, 2015 | Sep 11, 2015 | none ahead |
| GC Biopharma | 10 open or running | phase 3since Feb 19, 2018 | Feb 19, 2018 | none ahead |
| Kedrion | 11 open or running | phase 3since Dec 16, 2024 | Dec 16, 2024 | Dec 20, 2027phase 3 · NCT06752356 |
Also a collaborator on its studies: takeda-development-center-americas-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Sep 12, 2005.
- Sep 8, 2010Phase 3 study in Primary Immunodeficiency DiseasesCSL · NCT01199705 · 25 enrolled · Japan
- Jul 7, 2011Phase 4 study in Purpura, Thrombocytopenic, IdiopathicCSL · NCT01390649 · 57 enrolled · Bulgaria, Romania, Serbia
- Sep 11, 2015Takeda's first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to TakedaTakeda · NCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
- Mar 7, 2016Phase 4 study in Primary Immunodeficiency DiseasesCSL · NCT02711228 · 26 enrolled · Canada
- Feb 19, 2018GC Biopharma's first study: phase 3 study in Primary Immunodeficiency DiseasesNew to GC BiopharmaGC Biopharma · NCT03492710
- Sep 24, 2018Phase 4 study in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CSL · NCT03684018 · 30 planned · United States
- Oct 14, 20192 phase 2 studies in Scleroderma, DiffuseCSL · NCT04138485, NCT04137224
- Apr 10, 2020Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT04346108 · 17 enrolled · Japan
- Apr 11, 2021Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT04842643 · 12 enrolled · Japan
- Oct 10, 2021Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT05084053 · 26 enrolled · Japan
- Nov 24, 2021Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT05150340 · 16 enrolled · Japan
- Aug 22, 2022Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT05513586 · 15 enrolled · Japan
- Dec 16, 2024Kedrion's first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to KedrionKedrion · NCT06752356 · 161 planned · United States
- Jul 15, 2025Phase 4 study in Primary Immunodeficiency DiseasesCSL · NCT07076446 · 8 enrolled · United States
Ahead
- Dec 20, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingKedrion · NCT06752356
- Dec 20, 2029Primary completion: phase 4 study in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CSL · NCT03684018
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07076446Primary Immunodeficiency Diseases · United States | 4 | Completed | CSL | Jun 30, 2026 | 8 |
| NCT06752356Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States | 3 | Recruiting | Kedrion | Dec 20, 2027 | 161 |
| NCT05513586Primary Immunodeficiency Diseases · Japan | 3 | Completed | Takeda | Oct 30, 2025 | 15 |
| NCT05150340Primary Immunodeficiency Diseases · Japan | 3 | Completed | Takeda | Aug 28, 2023 | 16 |
| NCT05084053Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan | 3 | Completed | Takeda | Oct 28, 2025 | 26 |
| NCT04842643Primary Immunodeficiency Diseases · Japan | 3 | Completed | Takeda | Apr 25, 2024 | 12 |
| NCT04346108Primary Immunodeficiency Diseases · Japan | 3 | Completed | Takeda | Dec 22, 2021 | 17 |
| NCT04137224Scleroderma, Diffuse · Australia, Germany, Italy and more | 2 | Completed | CSL | May 17, 2022 | 27 |
| NCT04138485Scleroderma, Diffuse · United States, Argentina, Australia and more | 2 | Withdrawn | CSL | Sep 16, 2020 | 0 |
| NCT03684018Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · United States | 4 | Recruiting | CSL | Dec 20, 2029 | 30 |
| NCT03492710Primary Immunodeficiency Diseases | 3 | Withdrawn | GC Biopharma | Apr 30, 2019 | 0 |
| NCT02711228Primary Immunodeficiency Diseases · Canada | 4 | Completed | CSL | Jan 30, 2018 | 26 |
| NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Feb 23, 2022 | 138 |
| NCT01390649Purpura, Thrombocytopenic, Idiopathic · Bulgaria, Romania, Serbia | 4 | Completed | CSL | Sep 2014 | 57 |
| NCT01199705Primary Immunodeficiency Diseases · Japan | 3 | Completed | CSL | Aug 2011 | 25 |
| NCT00322556Agammaglobulinemia · United States | 3 | Completed | CSL | Apr 2008 | 55 |
| NCT00168038Purpura, Thrombocytopenic, Idiopathic · Germany, Italy, Poland and more | 3 | Completed | CSL | 58 | |
| NCT00168025Agammaglobulinemia | 3 | Completed | CSL | 89 | |
| NCT00168012Agammaglobulinemia | 3 | Completed | CSL | 42 |
How it is read
Names in the registry
- “IgPro10”, 4 entries
- “TAK-771”, 3 entries
- “Immunoglobulins Intravenous (Human)”, 3 entries
- “Immunoglobulin”, 2 entries
- “Immune globulin (human) 10% solution for intravenous administration”, 1 entry
Codes read as this program: IGPRO10.
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 8 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 4 studies
- Agammaglobulinemia, 3 studies
- Scleroderma, Diffuse, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.